Sun Pharma Corporate Overview

US Business - Significant Ramp-up in Sales Key Milestones in US SUN PHARMA 23 55 35 62 62 FY98 Sales in Rs. billion •Entry in US through Caraco acquisition 10 year CAGR - 16% FY10 •Acquired Taro Pharma - Entry into US dermatology market 137 138 135 FY13 98 87 107 FY17 105 101 3 3 3 3 3 3 3 3 3 2 2 © Sun Pharmaceutical Industries Limited. All Rights Reserved. FY18 •Acquired DUSA - Entry in branded specialty market •Tildrakizumab filing in US & Europe Acquired Ocular Technologies giving access to Cequa, a product for dry eyes. •Acquired Odomzo- branded oncology product from Novartis •Launched Odomzo in US •US FDA approval for Ilumya •Launched Ilumya & Yonsa in US •Received USFDA approval for Cequa FY19 •Launched Xelpros in US •Launched Ready-to-Infuse INFUGEM™ •Launched Cequa in US FY20 •Launched Absorica LD in US in Feb-2020 FY21 •Presented long term clinical data for Ilumya & other clinical insights for Odomzo & Levulan at American Academy of Dermatology Conference •Presented Pre-clinical data for GLP-1R agonist at American Diabetes Association Conference 19

View entire presentation